Vishal Manchanda from Nirmal Bang Securities speaks exclusively to ET Now and shares his views and expectation on the pharma sector and Dr. Reddy’s Lab quarter. Vishal states that they are expecting Dr. Reddy’s to post their growth on quarter to quarter basis and the growth this time would come largely on a domestic basis

According to ET NOW Poll, reported EBIDTA margins are expected at 23% vs 29.9% Year on Year. India rev is likely to grow by 20% on better traction. US sales are expected to grow 21% Year on Year to $250 million on new launches.


Source link

Leave a comment

Your email address will not be published. Required fields are marked *